McKesson (MCK)
(Delayed Data from NYSE)
$549.31 USD
+24.03 (4.57%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $576.76 +27.45 (5.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$549.31 USD
+24.03 (4.57%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $576.76 +27.45 (5.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
Top 5 Dividend Stocks to Cheer You Up This Holiday Season
by Sweta Killa
We have selected five dividend growth stocks ¿¿¿ H&R Block (HRB), ParkerHannifin (PH), Archer-Daniels-Midland (ADM), Insperity (NSP) and McKesson (MCK) ¿¿¿ that could be compelling picks for your portfolio ahead of the holiday season.
Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for CLRG
Invest Like Warren Buffett With These 3 Stocks
by Derek Lewis
Many investors mimic Warren Buffett, closely following all of his moves. And with his track record of success, it's easy to see why.
Is IQ Chaikin U.S. Large Cap ETF (CLRG) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for CLRG
McKesson (MCK) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter 2023 results benefit from segmental growth.
McKesson (MCK) Lags Q2 Earnings Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of -1.14% and 0.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Top 5 Stocks Set to Beat on Earnings After Markets Close
by Nalak Das
Five companies will report earnings results today after the closing bell. These are: CHK, MCK, ENLC, LTHM and ZI.
Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) first-quarter fiscal 2023 results are likely to reflect solid performance in the Pharmaceutical segment. However, inflation and supply chain constraints are likely to have continued.
MedTech Stocks Due to Report Earnings on Nov 1: MCK, CTLT & More
by Debanjana Dey
MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, CTLT, ECL, ABMD, HSIC and IDXX are placed ahead of their earnings releases.
Why Earnings Season Could Be Great for McKesson (MCK)
by Zacks Equity Research
McKesson (MCK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Zacks.com featured highlights include Heritage-Crystal Clean, Cadence Design Systems, McKesson and Schlumberger
by Zacks Equity Research
Heritage-Crystal Clean, Cadence Design Systems, McKesson and Schlumberger are part of the Zacks Screen of the Week article.
AmerisourceBergen (ABC) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
AmerisourceBergen (ABC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pick These 4 Stocks With Excellent Interest Coverage Ratio
by Sumit Singh
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as Heritage-Crystal (HCCI), Cadence (CDNS), McKesson (MCK) and Schlumberger (SLB) are capable of meeting financial obligations.
Merit Medical (MMSI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merit Medical (MMSI) delivered earnings and revenue surprises of 20.75% and 5.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) Q3 Earnings Miss, Operating Margin Up
by Zacks Equity Research
Boston Scientific's (BSX) Q3 revenues reflect double-digit organic revenue growth across the majority of its businesses.
NextGen Healthcare (NXGN) Q2 Earnings Beat, FY23 View Up
by Zacks Equity Research
NextGen's (NXGN) second-quarter fiscal 2023 results reflect strength in both its revenue sources.
Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q1 earnings are likely to have been driven by robust segmental performances.
Zacks Investment Ideas feature highlights: Elevance Health, McKesson and Humana
by Zacks Equity Research
Elevance Health, McKesson and Humana are part of Zacks Investment Ideas article.
3 Top-Ranked Medical Stocks Lapping the S&P 500
by Derek Lewis
All three stocks are up double-digit percentages in 2022, leaving the S&P 500's performance in the dust. With the stocks carrying favorable near-term earnings outlooks, the run could easily continue.
CVS Health (CVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
CVS Health's (CVS) digital capabilities are anticipated to have enhanced consumer engagement across all CVS Health businesses in Q3.
McKesson (MCK) to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Abiomed (ABMD) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q2 sales.
McKesson (MCK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) third-quarter results are likely to reflect continued strength in its Global Industrial segment.